Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 6/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090741 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2PTGDR | |
| SCHEMBL5093550 | 0.83 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2PTGDR | |
| SCHEMBL5093614 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HTR1D | |
| SCHEMBL6808310 | 0.71 | ESR1 (0.36) | SMN1; SMN2ALDH1A1THRBHTR1DHTR1B | |
| SCHEMBL5097946 | 0.70 | HTR1D (0.43) | ALDH1A1THRBHTR1DHTR1BKDM4C | |
| SCHEMBL6812077 | 0.70 | HTR1D (0.43) | ALDH1A1THRBHTR1DHTR1BKDM4C | |
| SCHEMBL5093583 | 0.70 | THRB (0.36) | PTGDRALDH1A1THRBHTR1DHTR1B | |
| SCHEMBL5566651 | 0.70 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5569919 | 0.70 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5092368 | 0.69 | HTR1D (0.36) | ALDH1A1THRBHTR1DHTR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | SMYD2 928/4885CYP3A4 1112/4885HTT 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.